Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
with docetaxel for the treatment of patients with metastaticbreast cancer. The third clinical stage antibody is MT293 (formerly D93);also known as TRC093 a first-in-class humanized monoclonal antibody thatinhibits angiogenesis and tumor cell growth by binding cleaved collagen.MT293 is licensed to TRACON Pharmaceuticals Inc. and is being developed ina phase 1 clinical trial for the treatment
Date:12/5/2007
with docetaxel for the treatment of patients with metastatic
breast cancer. The third clinical stage antibody is MT293 (formerly D93);
also known as TRC093, a first-in-class humanized monoclonal antibody that
inhibits angiogenesis and tumor cell growth by binding cleaved collagen.
MT293 is licensed to TRACON Pharmaceuticals, Inc. and is being developed in
a phase 1 clinical trial for the treatment of patients with cancer and age-
related macular degeneration. In addition, Micromet has established a
collaboration with Nycomed for the development and commercialization of
MT203, Micromet's human antibody neutralizing the activity of GM-CSF, which
has potential applications in the treatment of inflammatory diseases, such
as rheumatoid arthritis, as well as autoimmune diseases.
'/>"/>SOURCE Micromet, Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 Related biology technology :1.
Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference2.
Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum3.
Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings4.
Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference5.
Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 20076.
Micromet, Inc. Elects Joseph P. Slattery to Board of Directors7.
Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 20078.
Avicena Group to Present at Noble Financial Conference9.
Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA10.
Strategic Diagnostics to Present at Two Upcoming Investor Conferences11.
Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference